Metabolic Bone Disease Flashcards
Hx questions for metabolic bone disease
Risk factors:
- Exercise levels
- Smoker
- Co-morbidities (RA, T2DM)
- Nutrition, calcium intake
- Vitamin D exposure
- Prolonged amenorrhoea (when was your last period)
- Post menopausal age
- Malabsorption (coeliac, IBD)
Other:
- FHx
- Fracture history
- Pathological fracture: Any fracture from a fall from a standing height? * minimal trauma fracture: wrist, hip, spine
- Previous or current therapies for postmenopausal osteoporosis
- Rx: corticosteroids
Ix for osteoporosis
Pathology:
- FBE, U&Es, LFTs
- Pentad: Serum Ca and PO4, Vitamin D, PTH, Renal Function
- Thyroid (hyperthyroidism), cortisol,
- Myeloma screen: bone marrow aspirate, electrophoresis for free light chain in urine and serum (Bence Jones protein test in urine)
- Inflammatory marker: ESR, CRP
- Bone turnover markers: resporption serum b-CTX; formation P1NP (bone formation marker)
Radiology:
- Xray: lateral spine
- DEXA (
If you order serum Ca and PO4, what else needs to be ordered?
Pentad of tests that must be ordered to interpret one of them:
Serum Ca, PO4, Vitamin D, PTH, Renal Function
DEXA scan score components
T score: compared with normal peak bone mass person of same sex and ethnicity
Z score (in relation to ppl similar to you): compared with age, gender, ethinicity
Osteoporotic T score
Osteopaenic T score
Normal T score
> -1
For every 1 SD from normal, the relative risk of fracture increased by ___
1.5- to 2.5- fold
Sources of ALP
BLIP: Bone Liver instestine Placenta
What risk assessment tool is used to asses the absolute fracture risk?
FRAX- WHO:
WHO fracture risk assessment (Garvan Tool)
Rx of osteoporosis
a. HRT
b. Raloxifene (women only): SERM
c. Bisphosphonates - (Alendronate, Risedronate, Zolendronate)
e. Teriparatide
f. Denosumab
AFx of bisphosphonate
- GORD (make worse or new onset)
- osteonecrosis of jaw post dentition work when pulling out teeth. It leads to raw/open jaw bone and cannot heal with osteoclast inhibition
- eGFR
MoA of HRT
Normally osteoblasts produce RANKL binds to RANK receptor on osteoclasts leading to formation activity and survival stimulation
HRT and SERMs osteoblasts from releasing RANKL molecule
MoA of bisphosphonates
inhibit osteoclast action and increase osteoclast apoptosis
MoA of denosumab
RANKL inhibitor